News

Zila has amended the merger agreement with Tolmar Holding, a pharmaceutical research, development, manufacturing and commercial operations company, to reflect a higher price per share. Under the terms

Wyeth has provided the data from a phase 3 clinical study. The results showed that the investigational compound – bazedoxifene/conjugated estrogens (BZA/CE), reduced the frequency and severity of

ARIAD has provided the preliminary findings from two ongoing clinical trials. The study evaluated oral ridaforolimus in combination with trastuzumab (Herceptin) in patients with resistant, metastatic breast cancer

Acceleron and Celgene have initiated a second phase 2 clinical study of ACE-011. It is intended to treat chemotherapy-induced anemia in patients with metastatic breast cancer. Reportedly, phase

The Obesity Society has begun a five-year partnership with Healthy Interactions. The collaboration is aimed at developing educational materials using Healthy Interactions’ proprietary Conversation Map educational tools, to

CytRx has provided the results demonstrating that its cancer drug candidate – INNO-206 caused significant tumor shrinkage in an animal model of ovarian cancer. INNO-206, to be used

Cardiome has received a $15 million milestone payment from its collaboration with Merck, through an affiliate. Reportedly, the milestone was triggered by the submission of a Marketing Authorisation

Watson Pharmaceuticals has reported net income of $53 million or $0.46 per diluted share for the second quarter of 2009, compared to $60.3 million or $0.53 per diluted

The University of Queensland’s Institute for Molecular Bioscience (IMB) and Life Technologies have formed a scientific research collaboration to study pancreatic and ovarian cancer in Australia. The study